Cardiovascular and Interventional Radiological Society of Europe

September 10-14 | Barcelona, Spain

Science for people

September 10-14 | Barcelona, Spain

Science for people

September 10-14 | Barcelona, Spain

September 10-14 | Barcelona, Spain

September 10-14 | Barcelona, Spain

Science for people
Slider
IndustrySatellite symposia

Satellite symposia

Watch all CIRSE satellite symposia on demand to stay up to date on the latest industry developments!

Programme by day

BD
SY 402 Decades of continuous innovation – shaping the future of PAD patient care
13:00-14:00 CEST, Room 117

Moderators: K. Deloose (Dendermonde/BE), R. Langhoff (Berlin/DE)

402.1 The legacy of Lutonix™ a decade long proven track record
M. Brodmann (Graz/AT)

402.2 The Halo Effect™ innovation to reduce access site complications
R. Langhoff (Berlin/DE)

402.3 Recorded case innovations into practice
B. Migliara (Verona/IT)

402.4 The future for the PAD patient
K. Deloose (Dendermonde/BE)

402.5 Discussion

Boston Scientific
SY 403 Tumour cryoablation: long-term results and new indications…
13:00-14:00 CEST, Room 116

Moderator: A. Gangi (Strasbourg/FR)

T1a RCC cryoablation: should it now be standard of care?
D.J. Breen (Southampton/GB)

403.2 Cryoablation of bone metastases: a curative approach?
R.L. Cazzato (Strasbourg/FR)

403.3 New indications for cryoablation in soft-tissue neoplasms (endometriosis)
A. Gangi (Strasbourg/FR)

403.4 Cryoneurolysis
D. Filippiadis (Athens/GR)

 403.5 Round table

Abbott Vascular
SY 404 Looking beyond the intervention: how to improve management of patients with lower limb disease
13:00-14:00, Auditorium 2

Lunch bags available

Moderators: F. Fanelli (Florence/IT), T. Kröncke (Augsburg/DE)

404.1 Welcome

404.2 Peripheral artery disease – a look beyond the intervention
F. Fanelli (Florence/IT)

404.3 Lead by example: the importance of creating public awareness
D. Perkov (Zagreb/HR)

404.4 Lead by example: what is important for my patients, and how can I provide them with customised treatment and follow-up?
L. Patrone (London/GB)

404.5 Lead by example: achieving best patients’ results through a multidisciplinary approach – how to start a diabetic foot clinic
L. De Benito Fernández (Madrid/ES)

 404.6 Key takeaways

Guerbet
SY 405 Beyond access, does the catheter choice influence procedure success?
13:00-14:00, Room 115

Lunch bags available

Moderator: M. Little (Reading/GB)

405.1 Introduction

405.2 Deliver more
R. Gaba (Chicago, IL/US)

405.3 Minimising non-target embolisation
Y. Zaarour (Paris/FR)

405.4 Optimising beads delivery
S. Modi (London/GB)

405.5 Q&A

Medtronic
SY 608 Interventions for long, complex lesions in patients with critical limb ischaemia above- or below-the-knee
16:15-16:35, Room 116

Moderators: J. van den Berg (Lugano/CH)

608.1 Below-the-knee: the importance of vessel preparation to minimise acute complications and the need for stenting
J. Van Den Berg (Lugano/CH)

608.2 Above-the-knee: optimal tools and techniques for the treatment of complex femoropopliteal lesions
G. Tepe (Rosenheim/DE)

Cook Medical
SY 801 TIPS intervention: the earlier the better?
08:00-08:20, Room 112

Moderator: A. Moelker (Bergschenhoek/NL)

801.1 TIPS intervention: the earlier the better?
V. Hernandez-Gea (Barcelona/ES)

Boston Scientific
SY 1102 Complexity, comorbidities and under-served populations with PAD: the value of drug eluting technologies
11:30-12:30, Auditorium 1

Moderators: M. Brodmann (Graz/AT), G. Tepe (Rosenheim/DE)

1102.1 Introduction

1102.2 RCTs for drug eluting technology in PAD
M. Brodmann (Graz/AT)

1102.3 Real world patients and drug eluting technologies
S. Kum (Singapore/SG)

1102.4 Discussion

1102.5 Analysis of DET outcomes and SFA algorithm
S. Steiner (Leipzig/DE)

1102.6 What data do we still need?
G. Tepe (Rosenheim/DE)

1102.7 Discussion

1102.8 Regional challenges for drug eluting technologies
A. Justanaih (Riyadh/SA)

1102.9 ELEGANCE objectives and update
M. Brodmann (Graz/AT)

1102.10 Discussion

1102.11 Closing

Varian, A Siemens Healthineers Company
SY 1103 Optimising cryoablation in MSK
11:30-12:30, Room 116

Lunch bags available

Moderator: D. Breen (Southampton/GB)

1103.1 Versatility of cryoablation and patient selection
J. Jennings (Saint Luis, MO/US)

1103.2 Case review with discussion
T. Jakobs (Munich/DE), L. Crocetti (Pisa/IT)

Biotronik AG
SY 1104 The good for the bad and the ugly: how technology bailed me out of my worst cases
11:30-12:30, Auditorium 2

Moderator: C.A. Binkert (Winterthur/CH)

1104.1 Introduction

1104.2 My wire crossed but nothing else will, now what?
M.A. Ruffino (Turin/IT)

1104.3 The most hostile groin I ever saw
J. van den Berg (Lugano/CH)

1104.4 Bifurcations beyond challenging. What to do? – Discussion
P. Sbarzaglia (Cotignola/IT)

1104.5 Summary

Medtronic
SY 1105 Patient care algorithms for fistula creation & maintenance: case studies and data-driven decisions
11:30-12:30, Room 115

Lunch bags available

Moderator: F. Fanelli (Florence/IT)

1105.1 Welcome, introduction and background

1105.2 ESKD patient care: a nephrologist’s perspective
J. Ibeas (Barcelona/ES)

1105.3 Fistula creation: my experiences as a new Ellipsys user
F. Fanelli (Florence/IT)

1105.4 Fistula maintenance: how data informs my patient algorithm
A. Holden (Auckland/NZ)

1105.5 Panel discussion, Q&A and conclusions

Terumo Interventional Systems
SY 1202 New nitinol braided stent: crossing last frontier in the FemPop treatment
13:00-14:00, Auditorium 1

Lunch bags available

Moderator: K. Deloose (Dendermonde/BE)

1202.1 Opening

1202.2 State of the art in the FemPop treatment
M. Palena (Abano Terme/IT)

1202.3 Renzan stent & PRIZER study safety data & stent performance
K. Deloose (Dendermonde/BE)

1202.4 Case in the box with RenzanTM stent #1
Y. Goueffic (Nantes/FR)

1202.5 Case in the box with RenzanTM stent #2
M. Lichtenberg (Arnsberg/DE)

1202.6 Closing

BD
SY 1203 WavelinQ™ EndoAVF – not only creating an AV fistula but also making a difference
13:00-14:00, Auditorium 2

Moderator: F. Fanelli (Florence/IT)

1203.1 End stage kidney disease – the patient voice
D. Gallego (Valencia/IT)

1203.2 WavelinQ™ EndoAVF Clinical Program
P. Kitrou (Patras/GR)

1203.3 Recorded case with WavelinQ™ EndoAVF – the antiparallel option
O. Jaffer (London/GB)

1203.4 Recorded case with WavelinQ™ EndoAVF – the wrist approach
Y. Al Zahrani (Riyadh/SA)

1203.5 Secondary procedures in WavelinQ™ EndoAVF – a practical approach to diagnosis and intervention
C.A. Binkert (Winterthur/CH)

1203.7 Discussion

Boston Scientific
SY 1204 EPOCH: from the data to the patient
13:00-14:00, Room 116

1204.1 The EPOCH phase III trial
R. Salem (Chicago, IL/US)

1204.2 Understanding the technical aspects of treatment with Y-90 glass microspheres in mCRC
K. Fowers (Centerville, UT/US)

1204.3 Using the evidence in patient management
M. Lam (Utrecht/NL)

1204.4 Discussion/Q&A

Inari Medical
SY 1205 Advancing the treatment of VTE with lytic-free mechanical thrombectomy system
13:00-14:00, Room 114

Lunch bags available

Moderator: R. de Graaf (Friedrichshafen/DE)

1205.1 Patient selection for the interventional treatment of acute PE
B. Gebauer (Berlin/DE)

1205.2 Lytic-free thrombectomy in upper extremity DVT
R. de Graaf (Friedrichshafen/DE)

1205.3 Does the age of clot matter in the treatment of DVT?
A. Wigham (Oxford/GB)

1205.4 Lytic-free mechanical thrombectomy as part of the DVT treatment pathway
G. Grözinger (Tübingen/DE)

1205.5 Q&A

Philips
SY 1305 Innovating the procedure: integrated image-guidance for lower limb revascularisation
14:30-15:30, Room 117

Moderator: F. Fanelli (Florence/IT)

1305.1 Latest advances in intraprocedural imaging
C. von Stempel (London/GB)

1305.2 The benefit of IVUS-guided atherectomy for complex lesions
G. Korosoglou (Weinheim/DE)

1305.3 Optimising PTA outcomes with the Tack dissection repair system
D. van den Heuvel (Nieuwegein/NL)

1305.4 Image guided intervention in practice: can we optimise outcomes? Recorded case
M. Lichtenberg (Arnsberg/DE)

Guerbet
SY 1306 Optimising treatment approaches for HCC today
14:30-15:30, Room 116

Moderator: T. De Baère (Villejuif/FR)

1306.1 Introduction

1306.2 cTACE combined with ablation, real life practice today, guideline tomorrow?
C. Floridi (Ancona/IT)

1306.3 Is super-selective cTACE a key to success?
M. Ronot (Clichy/FR)

1306.4 Can cTACE partner with immunotherapy? A preliminary experience
L.J. Savic (Berlin/DE)

1306.5 Q&A

CASCINATION
SY 1307 CAS-One® IR – Technology. Evidence. Economics.
14:30-15:30, Room 115

Moderator: L. Crocetti (Pisa/IT)

1307.1 CAS-One IR – current and future technology
N. Shaida (Cambridge/GB)

1307.2 CAS-One IR – the evidence landscape
M. Beermann (Danderyd/SE)

1307.3 CAS-One IR – economic value
L. Lürken (Regensburg/DE)

1307.4 Discussion and Q&A

Medtronic
SY 1408 How to optimise interventional oncology outcomes using MWA
16:15-16:35, Room 119

Moderator: M. Meijerink (Amsterdam/NL)

1408.1 Optimise outcomes with reliability
M. Calandri (Turin/IT)

1408.2 Why sphericity in MWA is valuable for improved outcomes
M. Meijerink (Amsterdam/NL)

Guerbet
SY 1507 Lymphatic system: new horizons in visualisation and treatment
17:30-17:50, Room 114

Moderator: C.M. Sommer (Heidelberg/DE)

1507.1 Lymphatic system: new horizons in visualisation and treatment
M. Itkin (Philadelphia, PA/US)

1507.2 Q&A

IceCure Medical
SY 1508 Liquid nitrogen based cryoablation for optimal tumour destruction
17:30-18:10, Room 112

Main moderator: F. Orsi (Milan/IT)
Co-moderator: E. Atar (Petah Tikva/IL)

1508.1 Introduction

1508.2 Cryoablation close to the spinal cord: nerve protection
T. Kammoun (Nimes/FR)

1508.3 Cryoablation close to the nerves: nerve monitoring
L. Berny (Nimes/FR)

1508.4 Embolisation and cryoablation in a desmoid tumour – a combined approach therapy
T. Assa (Petah Tikva/IL)

1508.5 No limits in the cryoablation of breast lesions
L. Graña López (Lugo/ES)

1508.6 Q&A

Cook Medical
SY 1601 How interventionists can play a vital role in venous ulcer management
08:00-08:20, Room 112

1601.1 How interventionists can play a vital role in venous ulcer management
S. Black (London/GB)

Boston Scientific
SY 1902 Seeing clearly and clearing effectively: the utility of IVUS and thrombectomy in your practice
11:30-12:30, Auditorium 1

Moderator: G.J. O’Sullivan (Galway/IE)

1902.1 Introduction

1902.2 IVUS in vascular interventions: data, expert review and consensus
E. Secemsky (Boston/GB)

1902.3 Thrombectomy strategies in lower limb arterial intervention
G. Goyault (Strasbourg/FR)

1902.4 Thrombectomy strategies in venous intervention
N. Karunanithy (London/GB)

1902.5 Closing

Canon Medical Systems Europe B.V.
SY 1903 Redefine interventions with angio-CT
11:30-12:30, Room 115

Moderator: M. Hoffmann (Basel/CH)

1903.1 4DCT for liver interventions: still looking for the limits…
B. Guiu (Montpellier/FR)

1903.2 High-performance angio-CT: the powerful combination of high-def angio- and 4D-CT
T. Tanaka (Kashihara/JP)

Medtronic
SY 1904 Conversation with the experts: embolotherapy for the treatment of haemorrhage
11:30-12:30, Room 116

Lunch bags available

Moderator: F. Wolf (Vienna/AT)

1904.1 Welcome, introduction, and background

1904.2 Case presentation #1
A.M. Ierardi (Milan/IT)

1904.3 Case presentation #2
H. Lindgren (Helsinborg/SE)

1904.4 Case presentation #3
R. Loffroy (Dijon/FR)

1904.5 Case presentation #4
F. Wolf (Vienna/AT)

1904.6 Panel discussion and closing

Cook Medical
SY 1905 Complex, calcified lesions in the SFA – how to treat with predictable outcomes
11:30-12:30, Auditorium 2

 Moderator: M. Dake (Tucson, AZ/US)

1905.1 DES vs bypass: 36-month update and health economic snapshot from ZILVERPASS
M. Bosiers (Münster/DE)

1905.2 How I treat long TASC C&D lesions
K. Deloose (Dendermonde/BE)

1905.3 DES vs DCB+BMS: based on clinical evidence
S. Steiner (Leipzig/DE)

1905.4 How I treat long and calcified lesions
F. Fanelli (Florence/IT)

1905.5 How I treat long and calcified lesions
M. Manzi (Abano Therme/IT)

Terumo Interventional Systems
SY 2002 Building the evidence in treating HCC patients with the Holmium Platform
13:00-13:45, Room 117

Lunch bags available

Moderators: I. Bargellini (Florence/IT), J. Ricke (Munich/DE)

2002.1 Introduction

2002.2 HEPAR Primary
M. Lam (Utrecht/NL)

2002.3 RETOUCH
G. Verset (Brussels/BE)

2002.4 HOMIE-166
J. Ricke (Munich/DE)

2002.5 HOLMBRAVE
L. Tselikas (Villejuif/FR)

2002.6 Conclusion

BD
SY 2003 Latest data and treatment for iliofemoral DVT – improving quality of life
13:00-14:00, Auditorium 1

Moderator: M. Lichtenberg (Arnsberg/DE)

2003.1 Prospective multicentre evaluation of Aspirex™S in iliofemoral DVT treatment 1-month outcomes
R. Loffroy (Dijon/FR)

2003.2 Recorded case – from vessel preparation to iliofemoral DVT treatment, tips & tricks
M. Mirandola (Verona/IT)

2003.3 Recorded case – endovascular strategies for the treatment of May-Thurner syndrome
D. Baccellieri (Milan/IT)

2003.4 VERNACULAR trial – 36-month results of the Venovo™ Venous Stent System
G. O’Sullivan (Galway/IE)

2003.5 Discussion

Gore & Associates
SY 2004 Improving life in complex patient settings
13:00-14:00, Auditorium 2

Lunch bags available

Treatment of aortoiliac occlusive disease – the next generation of care

Moderator: A. Holden (Auckland/NZ),

2004.1 Welcome and introduction

2004.2 Aortoiliac occlusive disease, an increasingly complex condition – key advantages of covered stent treatment
R. Lely (Amsterdam/NL)

2004.3 VBX FLEX study. 5-year follow-up of patients with aortoiliac occlusive disease
A. Holden (Auckland/NZ)

2004.4 Conclusion

Small TIPS safety: what have we learned?

Moderator: G. Maleux (Leuven/BE)

2004.5 Welcome and introduction

2004.6 Pre-emptive TIPS is reducing complications and is life-saving. How to optimise treatment?
R. Loffroy (Dijon/FR)

2004.7 Early stage of ascites treatment: lessons learned using 8 mm covered TIPS stents
R. Miraglia (Palermo/IT)

2004.8 Conclusion

Siemens Healthineers
SY 2005 From embolisation to ablation: image guided therapy with the latest generation of imaging platforms
13:00-14:00, Room 116

Lunch bags available

Moderators: A. Gangi (Strasbourg/FR), F. Wacker (Hannover/DE)

2005.1 Precision in embolisation: scientific evidence for DynaCT applications
G. Grözinger (Tuebingen/DE)

2005.2 Imaging guidance in 2022: tackle challenges in IR with latest generation of angiography platform
B. Meyer (Hannover/DE)

2005.3 Needle procedures in CT: a fully integrated guidance tool that facilitates speed and accuracy
F. Wacker (Hannover/DE)

Shockwave Medical
SY 2104 Cracking the calcium conundrum in PAD treatment with Intravascular Lithotripsy (IVL)
14:30-15:30, Room 114

Moderator: A. Holden (Auckland/NZ)

2104.1 Change compliance, change the game!
A. Holden (Auckland/NZ)

2104.2 Why IVL preserves patient options
E. Alejandre-Lafont (St. Gallen/CH)

2104.3 Data to support our daily PAD practice
E. Blessing (Heidelberg/DE)

2104.4 Expanding the treatment boundaries in below-the-knee calcification
M. Palena (Abano Therme/IT)

2104.5 A sound, safe solution for CLTI
B.B Huasen (Lancashire/GB)

Philips
SY 2105 New imaging approaches in interventional oncology
14:30-15:30, Room 115

Moderator: C. Peña (Miami, FL/US)

2105.1 Improved hepatic tumour ablation; better outcomes and a small footprint
M. Smits (Utrecht/NL)

2105.2 Spectral CT as innovative imaging guidance in large lesions lung biopsies. XperGuide and Z-effective fusion for more defined targets, more diagnostic samplings and more biomarkers information
F. Piacentino (Varese/IT)

2105.3 Bridging the gap in IO with spectral angio-CT
M. Burgmans (Leiden/NL)

2105.4 Discussion

CORDIS
SY 2106 Exotic access and closure techniques for peripheral interventions
15:00-15:30, Room 113

2106.1 Evolution in the access sites in peripheral interventions. Choosing the best approach
A. Moelker (Bergschenhoek/NL)

2106.2 How I prevent vascular access complications with ultrasound guidance
A. Diamantopoulos (London/GB)

Medtronic
SY 2208 Approaching the venous patient: understanding the impact of patient reported outcomes in the treatment of disease in the deep venous system
16:15-16:35, Room 116

Moderator: G. Salazar (Chapel Hill, NC/US)

2208.1 Welcome, introduction, and background
G. Salazar (Chapel Hill, NC/US)

2208.2 ABRE study 24-month outcomes and case presentation
G. O’Sullivan (Galway/IE)

Medtronic
SY 2209 Approaching the venous patient: understanding the impact of patient reported outcomes in the treatment of disease in the superficial venous system
16:35-16:55, Room 116

Moderator: G. Salazar (Chapel Hill, NC/US)

2209.1 Welcome, introduction, background and a VenaSeal case
G. Salazar (Chapel Hill, NC/US)

2209.2 Patient treatment satisfaction and a VenaSeal case
C. Bicknell (London/GB)

Alvimedica
SY 2309 NiTiDES: answering uncertainties of today’s SFA DES
17:30-17:50, Room 119

Moderator: S. Müller-Hülsbeck (Flensburg/DE)

2309.1 Introduction

2309.2 Limitations of today’s SFA DES
S. Müller-Hülsbeck (Flensburg/DE)

2309.3 NiTiDESTM: the innovative technology able to meet the un-met
R. Langhoff (Berlin/DE)

2309.4 Coupling NiTiDESTM with Cre8TM BTK to optimise my complex CLI patients
M. Sirvent (Barcelona/ES)

2309.5 Discussion

2309.6 Take home messages & conclusion

Cook Medical
SY 2401 Haemorrhoid embolisation
08:00-08:20, Room 114

2401.1 Haemorrhoid embolisation
V. Vidal (Marseille/FR)

Penumbra
SY 2801 Introducing Indigo System Lightning 7 and 12 – the latest innovation in thrombus removal with Lightning computer aided aspiration
13:00-14:00, Auditorium 2

Lunch bags available

Moderator: S.D. Qanadli (Lausanne/CH)

2801.1 Management of acute limb ischaemia with Lightning 7 and 12
A. Wigham (Oxford/GB)

2801.2 My experience with Lightning 12 for the treatment of pulmonary embolism
A.R. Alvi (Birmingham/GB)

2801.3 Early experience in DVT thrombus removal with Lightning 12
G. O’Sullivan (Galway/IE)

Sirtex
SY 2802 Optimising outcomes with the SIR-Spheres advantage
13:00-14:00, Room 116

Lunch bags available

Moderator: P. Paprottka (Munich/DE)

2802.1 Welcome

2802.2 Real-world data with SIR-Spheres: learnings to improve the patient outcomes
N. Schäfer (Lausanne/CH)

2802.3 Tailoring SIRT with SIR-Spheres for optimal results: three patient scenarios
M. Martínez de la Cuesta (Pamplona/ES)

2802.4 Unparalleled flexibility with Order-Map-Treat & FLEXdose Delivery Programme: a case-based discussion
E. Bozzi (Pisa/IT)

2802.5 Discussion and close

Merit Medical
SY 2803 Expanding patient access with Merit WRAPSODY™, the cell-impermeable endoprosthesis designed to meet clinical challenges in AVF & AVG interventions
13:00-14:00, Room 115

Lunch bags available

Moderators: B. Dolmatch (Palo Alto, CA/US), F. Fanelli (Florence/IT)

2803.1 WRAPSODY cell-impermeable endoprosthesis: why develop the next generation covered stent?
B. Dolmatch (Palo Alto, CA/US)

2803.2 Recorded case: successful treatment of a challenging AV stenosis with WRAPSODY cell-impermeable endoprosthesis
T.M. Steinke (Düsseldorf/DE)

2803.3 Case presentations – the value of WRAPSODY cell-impermeable endoprosthesis in treating challenging AV dysfunctions – part 1
O. Jaffer (London/GB)

2803.4 Case presentations – the value of WRAPSODY cell-impermeable endoprosthesis in treating challenging AV dysfunctions – part 2
F. Fanelli (Florence/IT)

2803.5 Case presentations – how I reduce reintervention rates in my practice with WRAPSODY cell-impermeable endoprosthesis
T. Almeida Barroso (Brasília/BR)

2803.6 Q&A

PharmaCept GmbH
SY 2905 DSM-TACE: first clinical data of European studies in liver and lung
14:30-15:30, Room 114

Moderator: B. Gebauer (Berlin/DE)

2905.1 HEPAtocellular carcinoma: management with transarterial chemoembolisation with degradable STARch microspheres (DSM-TACE) – the HEPASTAR study
F. Collettini (Berlin/DE)

2905.2 Transfer of DSM experiences from liver to lung
K. Malagari (Athens/GR)

2905.3 First randomised study results on transpulmonary chemoembolisation (FASL) in the context of Frankfurt experience on TPCE of lung tumours
T.J. Vogl (Frankfurt/DE)

Kinepict Health Ltd
SY 2906 Digital variance angiography, a new era in X-ray angiography
14:30-15:30, Room 113

Moderators: A. Mahnken (Marburg/DE), B. Nemes (Budapest/HU)

2906.1 Introduction

2906.2 Potential benefits of DVA in prostatic artery embolisation
T.J. Vogl (Frankfurt/DE)

2906.3 Advantages of DVA in transarterial chemoembolisation of hepatocellular cancer
P. Lucatelli (Rome/IT)

2906.4 Dose management capabilities of DVA: radiation dose and contrast media reduction
P. Sótonyi (Budapest/HU)

2906.5 Operating room experience with DVA in CO2-assisted lower limb interventions
B. Nemes (Budapest/HU)

2906.6 DVA in lower limb angiography of patients with metal implants
R.P. Thomas (Oldenburg/DE)

2906.7 Concluding remarks